<DOC>
	<DOC>NCT02648035</DOC>
	<brief_summary>The purpose of this study is to evaluate the percentage of participants treated with subcutaneous (SC) Tocilizumab who are still on treatment after 52 weeks and the factors that play a major role in continuation of treatment.</brief_summary>
	<brief_title>EMBRACE-SC: Observational Study of Subcutaneous (SC) Tocilizumab Alone or in Combination With Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) in Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Aged &gt;/= 18 years of age with rheumatoid arthritis (RA) for whom the treating physician has made the decision to start subcutaneous (SC) Tocilizumab (TCZ) treatment according to approved label within 4 weeks prior to enrolment. Participants who have been receiving Tocilizumab (TCZ) for more than 4 weeks prior to enrolment. Participants who have received TCZ in past treatments. Participants who have received treatment with any investigational agent within 4 weeks (or 5 halflives of investigational agent, whichever is longer) of starting treatment TCZ SC. Participants with a history of autoimmune disease or of any joint inflammatory disease other than rheumatoid arthritis (RA).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>